BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
about
Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaTumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testingVariations of BRAF mutant allele percentage in melanomasNRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced MelanomaBRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanomaTransposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.In situ Protein Detection for Companion Diagnostics.The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells.CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer.A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France).Microscopes and Mass Spectrometers.Molecular pathology of cutaneous melanoma
P2860
Q34207132-65B693E3-7962-48B5-9F7A-B64298699DE7Q34667825-737ADB4D-CD34-41D3-882A-B8EAE87993ACQ34786402-7E4B7741-7E9D-4D2B-AC21-DC58EDAA9B38Q34970350-2F14E4F7-E747-41FA-B0E6-8DDD520EA1A9Q35682567-A960F3EC-8BA8-4897-8ADC-AECD5FB17B25Q35885523-61819B5B-EE1E-4D1F-B195-538CBA49B884Q35889462-0336F59A-2238-49C5-A9BE-2819F0860469Q36154050-F7D7F391-D70F-4115-BF98-19C78EB42F40Q36198169-B7E95E77-B117-4EDF-81EC-04529160A116Q36545907-A18B0AA0-5470-478F-A784-ED233EC1A4E8Q36833326-CB064EFF-8BFC-43C4-8328-43ED4273A074Q37038806-E61AB272-88EB-4DBC-9D3B-F2A47A5543A6Q37174935-FC71E787-FA64-4944-9905-877FEA750A40Q37270405-B3B624A4-B8A1-4ECA-998C-5648B007D775Q38620826-06DAD268-A17D-4D14-8CD6-7E5DAB216B67Q38838677-5D5374D8-34AE-4BD8-8ED7-880D8401FFBBQ38946743-35E56A81-5290-4ABF-9BDE-F54E3858C8B3Q38970503-52CED523-42FD-4D30-8B1A-B36F61121700Q39246718-5A2367BF-BCF1-45A7-A250-DDA54C82A5F3Q42551719-E8F557CA-0A4F-40F7-A7DB-B9757C03FD16Q48243218-14322AE4-09C5-40A2-BD98-89F05719F854Q54372069-209CD7AE-A61E-462F-99D1-B3F13C10BFFFQ55042787-CD3F653B-390B-4A4C-9B90-A2E7838460B6Q55340944-1240BEB7-86CA-460B-BA32-6735CD53EE10Q56428911-C8E3987B-424E-4B73-9C00-40C9FB9E65F2
P2860
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
BRAF(V600E) protein expression ...... AF(V600E) metastatic melanoma.
@ast
BRAF(V600E) protein expression ...... AF(V600E) metastatic melanoma.
@en
type
label
BRAF(V600E) protein expression ...... AF(V600E) metastatic melanoma.
@ast
BRAF(V600E) protein expression ...... AF(V600E) metastatic melanoma.
@en
prefLabel
BRAF(V600E) protein expression ...... AF(V600E) metastatic melanoma.
@ast
BRAF(V600E) protein expression ...... AF(V600E) metastatic melanoma.
@en
P2093
P2860
P50
P356
P1476
BRAF(V600E) protein expression ...... RAF(V600E) metastatic melanoma
@en
P2093
J F Thompson
J S Wilmott
P2860
P2888
P304
P356
10.1038/BJC.2013.29
P407
P50
P577
2013-02-12T00:00:00Z